Published in Drug Week, January 27th, 2006
This capital infusion will fund continued development of Doxa's biomaterials, primarily for use in orthopedics.
Doxa develops new biomaterials for medical use. Since 2002 efforts have been concentrated on the rapidly growing orthopedics sector where treatment of vertebral fractures has advanced most. In 2005 Doxa has conducted clinical trials with very good results. All patients with vertebral fractures felt significantly less pain. Operations are performed using minimal invasive surgery, which also leads to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.